Literature DB >> 22155556

Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients.

Peter Richardson1, Zhigang Duan, Jennifer Kramer, Jessica A Davila, Gia L Tyson, Hashem B El-Serag.   

Abstract

BACKGROUND & AIMS: Little information is available about what factors determine serum levels of alpha fetoprotein (AFP) (eg, demographic, virologic, or clinical features) among individuals who do not develop hepatocellular carcinoma (HCC). This information might improve AFP-based algorithms for HCC detection.
METHODS: We examined data from patients in the national Veterans' Affairs Hepatitis C Virus (HCV) Clinical Case Registry who received at least 1 AFP test (258,275 AFP tests in 76,357 patients; 1.9% developed HCC). We constructed hierarchical multivariate models of AFP levels. Potential predictors of AFP values included patients' sex, race, cirrhosis status, Model for End-Stage Liver Disease (MELD) score, HCV genotype, level of alanine aminotransferase (ALT) within 30 days before the AFP test, time to diagnosis of HCC, and time elapsed from the HCV index date.
RESULTS: Significant determinants for increased levels of AFP included presence of cirrhosis, higher MELD scores, and increased levels of ALT. AFP levels were also affected by the interaction between ALT levels and the presence and time to development of HCC. Among patients who did not have HCC, the AFP level increased with the level of ALT; the AFP values in the presence of ALT 37-56 U/L, ALT 57-92 U/L, or ALT >92 U/L were 16%, 35%, and 68% higher, respectively, than AFP values at ALT 0-36 U/L. However, patients who developed HCC within 30 days of receiving the AFP test had a lower rate of increase in AFP with each higher category of ALT level, with increases of 31%, 39%, and 37% for the same respective ALT categories.
CONCLUSIONS: In patients with chronic HCV infection, AFP and ALT values correlate; however, among patients with HCC, levels of AFP increase disproportionately to or unaccompanied by increases in levels of ALT. The prognostic and diagnostic value of AFP levels might be increased by adjusting for ALT values. Copyright Â
© 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155556      PMCID: PMC3311729          DOI: 10.1016/j.cgh.2011.11.025

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  19 in total

1.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Authors:  Adrian M Di Bisceglie; Richard K Sterling; Raymond T Chung; James E Everhart; Jules L Dienstag; Herbert L Bonkovsky; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; William M Lee; Timothy R Morgan; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

2.  Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.

Authors:  Hashem B El-Serag; Jennifer R Kramer; G John Chen; Zhigang Duan; Peter A Richardson; Jessica A Davila
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

3.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

Review 4.  Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis.

Authors:  Samir Gupta; Stephen Bent; Jeffrey Kohlwes
Journal:  Ann Intern Med       Date:  2003-07-01       Impact factor: 25.391

5.  Utilization of screening for hepatocellular carcinoma in the United States.

Authors:  Jessica A Davila; Allan Weston; Walter Smalley; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2007-09       Impact factor: 3.062

6.  Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.

Authors:  Maurizio Soresi; Carmela Magliarisi; Pietro Campagna; Gaetano Leto; Giulio Bonfissuto; Anna Riili; Antonio Carroccio; Roberta Sesti; Silvio Tripi; Giuseppe Montalto
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

7.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

8.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

9.  Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.

Authors:  Tsung-Ming Chen; Pi-Teh Huang; Ming-Hung Tsai; Lien-Fu Lin; Chung-Cheng Liu; Ka-Sic Ho; Chuan-Pau Siauw; Po-Liang Chao; Jai-Nien Tung
Journal:  J Gastroenterol Hepatol       Date:  2007-05       Impact factor: 4.029

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  25 in total

Review 1.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

2.  The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis.

Authors:  Donna L White; Peter Richardson; Nabiha Tayoub; Jessica A Davila; Fasiha Kanwal; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2015-10-28       Impact factor: 22.682

3.  Hepatocellular Carcinoma: Current Questions and Future Directions.

Authors:  Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-03

4.  Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis.

Authors:  Nabihah Tayob; Israel Christie; Peter Richardson; Ziding Feng; Donna L White; Jessica Davila; Douglas A Corley; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2018-12-14       Impact factor: 11.382

5.  Low Plasma Zinc Is Associated with Higher Mitochondrial Oxidative Stress and Faster Liver Fibrosis Development in the Miami Adult Studies in HIV Cohort.

Authors:  Sabrina S Martinez; Adriana Campa; Yinghui Li; Christina Fleetwood; Tiffanie Stewart; Venkataraghavan Ramamoorthy; Marianna K Baum
Journal:  J Nutr       Date:  2017-02-22       Impact factor: 4.798

6.  Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase.

Authors:  Ju Dong Yang; Jianliang Dai; Amit G Singal; Purva Gopal; Benyam D Addissie; Mindie H Nguyen; Alex S Befeler; K Rajender Reddy; Myron Schwartz; Denise M Harnois; Hiroyuki Yamada; Gregory J Gores; Ziding Feng; Jorge A Marrero; Lewis R Roberts
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-03       Impact factor: 4.254

7.  A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson
Journal:  Gastroenterology       Date:  2014-01-23       Impact factor: 22.682

Review 8.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis.

Authors:  Myron John Tong; Thatcher Thi Huynh; Surachate Siripongsakun; Patrick Weijen Chang; Lori Terese Tong; Yen Phi Ha; Edward Alphonso Mena; Matthew Frank Weissman
Journal:  Hepatol Int       Date:  2015-07-30       Impact factor: 6.047

10.  Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.

Authors:  John B Kisiel; Brian A Dukek; Reddappa V S R Kanipakam; Hassan M Ghoz; Tracy C Yab; Calise K Berger; William R Taylor; Patrick H Foote; Nasra H Giama; Kristeen Onyirioha; Mohamed A Abdallah; Kelli N Burger; Seth W Slettedahl; Douglas W Mahoney; Thomas C Smyrk; Jason T Lewis; Maria Giakoumopoulos; Hatim T Allawi; Graham P Lidgard; Lewis R Roberts; David A Ahlquist
Journal:  Hepatology       Date:  2019-02-05       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.